tiprankstipranks
Advertisement
Advertisement
Analyst Reiterates Buy on ProMIS Neurosciences, Maintains $18 Price Target on Differentiated Alzheimer’s Candidate PMN310
PremiumRatingsAnalyst Reiterates Buy on ProMIS Neurosciences, Maintains $18 Price Target on Differentiated Alzheimer’s Candidate PMN310
1M ago
Ram Selvaraju Reiterates Buy on ProMIS Neurosciences, Maintains $18 12-Month Price Target on Differentiated PMN310 Alzheimer’s Profile
Premium
Ratings
Ram Selvaraju Reiterates Buy on ProMIS Neurosciences, Maintains $18 12-Month Price Target on Differentiated PMN310 Alzheimer’s Profile
2M ago
ProMIS Neurosciences shareholders approve directors and incentive plan
Premium
Company Announcements
ProMIS Neurosciences shareholders approve directors and incentive plan
2M ago
ProMIS Neurosciences files to sell 13.83M common shares for holders
PremiumThe FlyProMIS Neurosciences files to sell 13.83M common shares for holders
4M ago
Promis Neurosciences Inc trading resumes
Premium
The Fly
Promis Neurosciences Inc trading resumes
6M ago
Promis Neurosciences Inc trading halted, volatility trading pause
Premium
The Fly
Promis Neurosciences Inc trading halted, volatility trading pause
6M ago
ProMIS Neurosciences: Buy Rating Backed by Innovative EpiSelect™ Platform and Promising PMN310 Candidate
PremiumRatingsProMIS Neurosciences: Buy Rating Backed by Innovative EpiSelect™ Platform and Promising PMN310 Candidate
8M ago
ProMIS Neurosciences: Buy Rating Affirmed Amid Promising PMN310 Progress and Favorable Valuation
Premium
Ratings
ProMIS Neurosciences: Buy Rating Affirmed Amid Promising PMN310 Progress and Favorable Valuation
8M ago
ProMIS Neurosciences target adjusted to $18 from $4 at H.C. Wainwright
Premium
The Fly
ProMIS Neurosciences target adjusted to $18 from $4 at H.C. Wainwright
8M ago

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100